CSL CEO on Results, Global Business Outlook

Aug. 14 (Bloomberg) -- Paul Perreault, chief executive officer of CSL Ltd., the world’s second-biggest maker of blood-derived therapies, talks about the company's financial performance and business outlook. CSL, reported a 19 percent jump in annual profit, boosted by demand in the U.S. and Europe for Hizentra, an infection-fighting infusion. Perreault speaks with Susan Li on Bloomberg Television's "First Up." (Source: Bloomberg)
Square Rival iZettle Raises $67M From Intel and Zouk
37:12 - Today’s "BWest Byte" is $67 million, for how much iZettle, a Swedish payments startup and rival to Jack Dorsey's Square, has raised from Intel and Zouk. Bloomberg's Matt Miller reports on "Bloomberg West." (Source: Bloomberg)
  • What's Next for Flexible Electronic Technology?
  • Facebook Cracks Down on Video Pirates
  • Deep Dive: Is Market Turmoil Hurting Consumer Sentiment?